Osteoporosis Treatment, Fracture Prevention, and Healthy Ageing

Key Takeaways

Osteoporosis matters to healthy ageing principally because fragility fractures can impair mobility and independence; hip fracture is also associated with substantial excess mortality, although the fracture is partly a marker of underlying frailty and illness. [1] [2]
Randomized trials show that several antiresorptive and bone-forming medicines reduce vertebral fractures, and selected treatments also reduce hip or other nonvertebral fractures in populations at sufficiently high baseline risk. [4] [5] [6] [7]
Absolute benefit depends on starting risk. Prior fragility fracture, fracture site, bone mineral density, age, falls, and other clinical factors therefore matter more than a drug's relative-risk reduction alone. [1] [3] [4]
Treatment duration and stopping rules are therapy-specific: bisphosphonate effects can persist after discontinuation, whereas stopping denosumab can produce rapid bone loss and multiple vertebral fractures in some patients. [10] [11]
Fracture prevention can preserve function, but most osteoporosis trials test fractures and bone outcomes rather than biological ageing or lifespan. [1] [9]

Who This Is Useful For

This page is for readers interpreting osteoporosis treatment as part of healthy ageing. It distinguishes changes in bone mineral density from clinically important fracture outcomes, explains why prior fracture changes absolute benefit, and separates evidence for preserving mobility from broader claims about ageing or longevity. [1] [3]

What Is Being Treated

Osteoporosis is a skeletal disorder in which reduced bone strength raises susceptibility to fracture. Dual-energy X-ray absorptiometry provides a bone mineral density measure, but clinical assessment also considers prior fractures and other risk factors because density alone does not capture all fracture risk. In adults over 50, a hip or vertebral fragility fracture can establish clinically important skeletal fragility even when a later density value is not in the osteoporotic range. [1]

Fracture risk is dynamic. In a population cohort, risk of a second major osteoporotic fracture was highest soon after the first and remained above population risk during follow-up. This makes a recent fracture both an injury and a marker of near-term vulnerability. [3]

Evidence at a Glance

Intervention domain	What the evidence measures	What it supports	Main limitation
Bisphosphonates	Placebo-controlled trials measured radiographic vertebral, clinical, nonvertebral, and hip fractures. [4] [5]	Alendronate and zoledronic acid reduce fractures in appropriately selected postmenopausal women; zoledronic acid also reduced recurrent fractures after hip-fracture repair. [4] [5] [9]	Benefits differ by baseline risk, fracture site, agent, duration, and trial population. [1] [4]
Denosumab	FREEDOM measured new vertebral, nonvertebral, and hip fractures over 36 months. [6]	RANKL inhibition reduced all three fracture categories in postmenopausal women with osteoporosis. [6]	The effect is not retained like a bisphosphonate residual effect; discontinuation requires separate interpretation. [11]
Bone-forming or dual-action therapy	Active-comparator trials measured new vertebral and clinical fractures in women at high or very high risk. [7] [8]	Teriparatide outperformed risedronate for vertebral and clinical fractures in VERO; romosozumab followed by alendronate outperformed alendronate alone for several fracture outcomes in ARCH. [7] [8]	These results come from selected, high-risk postmenopausal populations and do not imply the same benefit-risk balance at low baseline risk. [7] [8]
Exercise and falls prevention	Randomized-trial meta-analyses measure falls, fall-related injury, and fractures. [12]	Exercise programmes can reduce falls and fall-related fractures in older adults. [12]	Programmes, participants, adherence, and fracture ascertainment vary, and fracture events are less common than falls. [12]
Coordinated post-fracture care	Controlled studies of fracture liaison services measure assessment, treatment initiation, adherence, refracture, and mortality. [13]	Systematic follow-up improves delivery of secondary prevention and is associated with fewer refractures. [13]	The evidence combines randomized and observational designs, so mortality estimates are less secure than treatment-process outcomes. [13]

Antiresorptive Treatment and Fracture Outcomes

Antiresorptive medicines reduce osteoclast-mediated bone resorption. In the Fracture Intervention Trial, alendronate reduced clinical fractures among women whose femoral-neck density met the study's osteoporosis threshold, but not among women with higher bone density; radiographic vertebral fractures were reduced across the broader low-density group. The contrast shows why baseline risk changes absolute and sometimes detectable clinical benefit. [4]

In HORIZON-PFT, yearly zoledronic acid for three years reduced morphometric vertebral fractures from 10.9% to 3.3% and hip fractures from 2.5% to 1.4% among postmenopausal women with osteoporosis. FREEDOM similarly found that denosumab reduced new vertebral, nonvertebral, and hip fractures over three years. These are direct fracture outcomes, not inferences made from bone density alone. [5] [6]

Bone Formation, Sequence, and Starting Risk

Teriparatide stimulates bone formation through intermittent parathyroid-hormone-receptor signalling. In VERO, women with severe osteoporosis and vertebral fractures had fewer new radiographic vertebral fractures with teriparatide than with risedronate over 24 months; the difference in nonvertebral fragility fractures was not statistically significant. [7]

Romosozumab inhibits sclerostin, increasing formation while also decreasing resorption. In ARCH, one year of romosozumab followed by alendronate reduced new vertebral, clinical, nonvertebral, and hip fractures compared with alendronate alone in women with osteoporosis and a fragility-fracture history. Serious cardiovascular events were numerically more frequent during the romosozumab year, leaving treatment selection dependent on both skeletal and cardiovascular context. [8]

After a Fragility Fracture

A fragility fracture predicts another fracture particularly strongly in the following years. That temporal pattern makes the post-fracture period important for identifying osteoporosis, contributors to falls, and barriers to treatment continuity. [3] [13]

HORIZON's recurrent-fracture trial enrolled patients after surgical repair of a low-trauma hip fracture. Zoledronic acid given within 90 days reduced new clinical fractures from 13.9% to 8.6% over a median 1.9 years. All-cause mortality was also lower, but that survival result comes from one specific post-hip-fracture trial and should not be generalized to every osteoporosis medicine or population. [9]

Fracture liaison services address a different part of the problem: the gap between an index fracture and later assessment or treatment. A meta-analysis found better bone-density testing, treatment initiation, and adherence, alongside lower refracture rates; mixed study designs make the process outcomes more causally persuasive than the reported mortality association. [13]

Falls, Function, and the Non-Drug Pathway

Fracture risk reflects both skeletal strength and the forces applied during a fall. Exercise trials therefore target balance, strength, and fall exposure rather than bone turnover alone. A meta-analysis of randomized trials in older adults found fewer fall-related fractures with exercise, while also noting variation across programmes and the limited number of fracture events. [12]

Drug and non-drug evidence answer different questions. An antiresorptive trial tests whether changing bone remodelling reduces fractures; a falls-prevention trial tests whether reducing falls or improving recovery responses reduces injuries. A comprehensive fracture model can include both pathways without assuming that one substitutes for the other. [1] [12]

Duration, Discontinuation, and Rare Harms

Osteoporosis therapies do not share one stopping rule. In FLEX, women who stopped alendronate after about five years lost some bone density but did not have more nonvertebral fractures over the next five years; continuing treatment reduced clinical vertebral fractures. The trial supports risk reassessment rather than a universal assumption that all patients either stop or continue indefinitely. [10]

Denosumab is different because bone turnover can rebound after a delayed or final dose. Post hoc analyses of FREEDOM and its extension found that multiple vertebral-fracture rates after discontinuation were higher following longer exposure, although these analyses were exploratory and based on subsets with follow-up radiographs. [11]

Long-term bisphosphonate exposure is associated with atypical femoral fracture, but the absolute event rate is low and rises with duration. In a large cohort, modeled reductions in conventional osteoporotic and hip fractures generally exceeded the increase in atypical fractures, with the balance varying by duration and patient characteristics. This is why rare-harm discussions require absolute as well as relative risks. [14]

Healthy Ageing and Survival

Preventing vertebral and hip fractures is relevant to healthy ageing because fractures can produce pain, disability, loss of mobility, and dependence. Hip fracture is associated with sharply elevated short-term mortality and persistent excess mortality, but observational studies cannot determine how much is caused by the fracture itself rather than the frailty and disease that preceded it. [1] [2]

Most pivotal osteoporosis trials were designed around fractures, bone density, and safety rather than biological-age measures or lifespan. The post-hip-fracture zoledronic-acid trial reported lower mortality, but the broader evidence base supports a narrower conclusion: effective treatment can reduce defined fracture outcomes in selected risk groups. It does not establish generalized slowing of ageing. [4] [5] [6] [9]

Evidence Quality and Interpretation

Confidence is high that multiple osteoporosis medicines reduce vertebral fractures in the populations represented in randomized trials. Evidence for hip and nonvertebral fractures is more agent- and population-specific, and absolute reductions are larger when baseline fracture risk is higher. [4] [5] [6] [7]

Generalizability requires care. Many pivotal trials enrolled postmenopausal women, often with density-defined osteoporosis or prior fracture; evidence cannot automatically be transferred to younger adults, men, people with secondary causes of bone loss, or those at low absolute risk. Active-comparator trials in severe disease answer a different question from placebo-controlled trials in broader low-density populations. [1] [4] [7] [8]

Confidence is lower for lifespan effects. Excess mortality after hip fracture is well documented, but it is partly confounded by underlying health; mortality reduction has not been a consistent primary finding across osteoporosis drug trials. [2] [9]

What This Does Not Mean

It does not mean that a higher bone-density result guarantees that a fracture has been prevented; fracture endpoints remain the more direct clinical evidence. [4] [5]
It does not mean that all osteoporosis medicines are interchangeable in mechanism, duration, stopping effects, or evidence by fracture site. [1] [10] [11]
It does not mean that a large relative-risk reduction produces a large absolute benefit in someone whose untreated fracture risk is low. [1] [4]
It does not mean that fracture prevention has been shown to slow biological ageing, even when maintaining mobility and independence is relevant to healthy ageing. [1] [9]

Practical Interpretation Examples

If a trial reports a 50% relative reduction: compare event rates in both groups; the absolute difference depends on starting risk and follow-up time. [4] [5]
If bone density improves: check whether the study also measured vertebral, hip, or nonvertebral fractures rather than treating density as a complete substitute. [5] [6]
If treatment is being stopped: identify the drug, exposure duration, and current fracture risk; residual and rebound effects differ between bisphosphonates and denosumab. [10] [11]
If mortality is lower after treatment: determine whether mortality was prespecified, whether the population had a recent hip fracture, and whether the finding has been reproduced in other settings. [9]

References

LeBoff, M. S., et al. (2022). The clinician's guide to prevention and treatment of osteoporosis. Osteoporosis International. https://pubmed.ncbi.nlm.nih.gov/35478046/
Haentjens, P., et al. (2010). Meta-analysis: excess mortality after hip fracture among older women and men. Annals of Internal Medicine. https://pubmed.ncbi.nlm.nih.gov/20231569/
Johansson, H., et al. (2017). Imminent risk of fracture after fracture. Osteoporosis International. https://pubmed.ncbi.nlm.nih.gov/28028554/
Cummings, S. R., et al. (1998). Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. https://pubmed.ncbi.nlm.nih.gov/9875874/
Black, D. M., et al. (2007). Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. The New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/17476007/
Cummings, S. R., et al. (2009). Denosumab for prevention of fractures in postmenopausal women with osteoporosis. The New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/19671655/
Kendler, D. L., et al. (2018). Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. The Lancet. https://pubmed.ncbi.nlm.nih.gov/29129436/
Saag, K. G., et al. (2017). Romosozumab or alendronate for fracture prevention in women with osteoporosis. The New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/28892457/
Lyles, K. W., et al. (2007). Zoledronic acid and clinical fractures and mortality after hip fracture. The New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/17878149/
Black, D. M., et al. (2006). Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX). JAMA. https://pubmed.ncbi.nlm.nih.gov/17190893/
Cosman, F., et al. (2022). Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM Extension trials additional post hoc analyses. Journal of Bone and Mineral Research. https://pubmed.ncbi.nlm.nih.gov/36088628/
Wang, Q., et al. (2020). Effectiveness of exercise intervention on fall-related fractures in older adults: a systematic review and meta-analysis of randomized controlled trials. BMC Geriatrics. https://pubmed.ncbi.nlm.nih.gov/32887571/
Wu, C. H., et al. (2018). Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: a systematic literature review and meta-analysis. Bone. https://pubmed.ncbi.nlm.nih.gov/29555309/
Black, D. M., et al. (2022). Bisphosphonates and the risk of atypical femur fractures. Bone. https://pubmed.ncbi.nlm.nih.gov/34920168/

Educational Disclaimer

This page summarizes population and clinical-trial evidence and does not provide a diagnosis, treatment recommendation, or individualized medical advice. Osteoporosis assessment and treatment depend on fracture history, bone density, age, fall risk, kidney function, coexisting conditions, prior therapies, and other clinical factors.